Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quince Therapeutics, Inc.QNCX · Entity 7403 | Director · Chief Corp. Affairs Officer | May 18, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quince Therapeutics, Inc.
Report date May 18, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.09 · Expires 2031-03-01 | Direct | 34,675 |
Reported balance
After 2026-05-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-18 · Grant · Acquired 34,675 · Balance 34,675 F1: Received in exchange for a stock option to acquire 50,000 shares of Orphai Therapeutics, LLC ("Orphai") common stock with an exercise price of $0.06 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the "Merger Agreement"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Orphai Holdings Therapeutics, Inc., a Delaware corporation ("HoldCo") and Orphai. F2: Immediately exercisable. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.09 · Expires 2032-04-07 | Direct | 228,855 |
Reported balance
After 2026-05-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-18 · Grant · Acquired 228,855 · Balance 228,855 F3: Received in exchange for stock options to acquire an aggregate of 330,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2: Immediately exercisable. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.09 · Expires 2032-09-05 | Direct | 124,830 |
Reported balance
After 2026-05-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-18 · Grant · Acquired 124,830 · Balance 124,830 F4: Received in exchange for stock options to acquire an aggregate of 180,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2: Immediately exercisable. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.09 · Expires 2033-07-30 | Direct | 69,350 |
Reported balance
After 2026-05-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-18 · Grant · Acquired 69,350 · Balance 69,350 F5: Received in exchange for stock options to acquire an aggregate of 100,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2: Immediately exercisable. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.09 · Expires 2034-03-14 | Direct | 362,092 |
Reported balance
After 2026-05-18 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-18 · Grant · Acquired 362,092 · Balance 362,092 F6: Received in exchange for stock options to acquire an aggregate of 522,124 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2: Immediately exercisable. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.09 · Expires 2034-08-12 | Direct | 133,615 |
Reported balance
After 2026-05-18 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-18 · Grant · Acquired 133,615 · Balance 133,615 F7: Received in exchange for stock options to acquire an aggregate of 192,668 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2: Immediately exercisable. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.09 · Expires 2036-03-15 | Direct | 2,070,107 |
Reported balance
After 2026-05-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-18 · Grant · Acquired 2,070,107 · Balance 2,070,107 F8: Received in exchange for stock options to acquire an aggregate of 2,985,015 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2: Immediately exercisable. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2036-05-11 | Direct | 6,837,319 |
Reported balance
After 2026-05-18 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-18 · Grant · Acquired 6,837,319 · Balance 6,837,319 F9: Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement. F2: Immediately exercisable. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2036-05-11 | Direct | 6,837,319 |
Reported balance
After 2026-05-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-18 · Grant · Acquired 6,837,319 · Balance 6,837,319 F9: Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement. F10: Beginning May 21, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the Orphai's 2026 Stock Incentive Plan) wih the Issuer as of each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Received in exchange for a stock option to acquire 50,000 shares of Orphai Therapeutics, LLC ("Orphai") common stock with an exercise price of $0.06 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the "Merger Agreement"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Orphai Holdings Therapeutics, Inc., a Delaware corporation ("HoldCo") and Orphai.
F2: Immediately exercisable.
F3: Received in exchange for stock options to acquire an aggregate of 330,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.
F4: Received in exchange for stock options to acquire an aggregate of 180,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.
F5: Received in exchange for stock options to acquire an aggregate of 100,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.
F6: Received in exchange for stock options to acquire an aggregate of 522,124 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.
F7: Received in exchange for stock options to acquire an aggregate of 192,668 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.
F8: Received in exchange for stock options to acquire an aggregate of 2,985,015 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement.
F9: Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement.
F10: Beginning May 21, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the Orphai's 2026 Stock Incentive Plan) wih the Issuer as of each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (Right to Buy) · Derivative | 6,837,319 | Not disclosed Strike: $0.84 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 9 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,837,319 Underlying: Common Stock · 6,837,319 shares Expires 2036-05-11 F9 · kind: Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement. F9 · price: Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement. F10 · derivative.exercise_date: Beginning May 21, 2026, the shares subject to the option vest in a series of thirty-six (36) successive equal monthly installments, subject to the Reporting Person's Continued Service (as defined in the Orphai's 2026 Stock Incentive Plan) wih the Issuer as of each such vesting date. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (Right to Buy) · Derivative | 6,837,319 | Not disclosed Strike: $0.84 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 8 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,837,319 Underlying: Common Stock · 6,837,319 shares Expires 2036-05-11 F9 · kind: Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement. F9 · price: Received in exchange for stock options to acquire an aggregate of 9,859,148 shares of Orphai common stock with an exercise price of $0.58 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (Right to Buy) · Derivative | 2,070,107 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 7 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,070,107 Underlying: Common Stock · 2,070,107 shares Expires 2036-03-15 F8 · kind: Received in exchange for stock options to acquire an aggregate of 2,985,015 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F8 · price: Received in exchange for stock options to acquire an aggregate of 2,985,015 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (Right to Buy) · Derivative | 133,615 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 6 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,615 Underlying: Common Stock · 133,615 shares Expires 2034-08-12 F7 · kind: Received in exchange for stock options to acquire an aggregate of 192,668 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F7 · price: Received in exchange for stock options to acquire an aggregate of 192,668 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (Right to Buy) · Derivative | 362,092 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 5 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,092 Underlying: Common Stock · 362,092 shares Expires 2034-03-14 F6 · kind: Received in exchange for stock options to acquire an aggregate of 522,124 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F6 · price: Received in exchange for stock options to acquire an aggregate of 522,124 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (Right to Buy) · Derivative | 69,350 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 4 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,350 Underlying: Common Stock · 69,350 shares Expires 2033-07-30 F5 · kind: Received in exchange for stock options to acquire an aggregate of 100,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F5 · price: Received in exchange for stock options to acquire an aggregate of 100,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (Right to Buy) · Derivative | 124,830 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 3 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,830 Underlying: Common Stock · 124,830 shares Expires 2032-09-05 F4 · kind: Received in exchange for stock options to acquire an aggregate of 180,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F4 · price: Received in exchange for stock options to acquire an aggregate of 180,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (Right to Buy) · Derivative | 228,855 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 2 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,855 Underlying: Common Stock · 228,855 shares Expires 2032-04-07 F3 · kind: Received in exchange for stock options to acquire an aggregate of 330,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F3 · price: Received in exchange for stock options to acquire an aggregate of 330,000 shares of Orphai common stock with an exercise price of $0.06 per share pursuant to the Merger Agreement. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| May 18, 2026 Filed Jun 11, 2026 21:30 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (Right to Buy) · Derivative | 34,675 | Not disclosed Strike: $0.09 | Not disclosed |
DisclosureSEC source: 0001346566-26-000004 · form4-06112026_090603.xml · derivative · entry 1 Roberts Brigette · CIK 0001346566 · Director · Chief Corp. Affairs Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,675 Underlying: Common Stock · 34,675 shares Expires 2031-03-01 F1 · kind: Received in exchange for a stock option to acquire 50,000 shares of Orphai Therapeutics, LLC ("Orphai") common stock with an exercise price of $0.06 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the "Merger Agreement"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Orphai Holdings Therapeutics, Inc., a Delaware corporation ("HoldCo") and Orphai. F1 · price: Received in exchange for a stock option to acquire 50,000 shares of Orphai Therapeutics, LLC ("Orphai") common stock with an exercise price of $0.06 per share pursuant to an Agreement and Plan of Merger, dated May 17, 2026 (the "Merger Agreement"), by and among the Issuer, Phoenix Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of the Issuer ("First Merger Sub"), Phoenix Merger Sub II, LLC, a Delaware limited liability company and wholly owned subsidiary of the Issuer ("Second Merger Sub"), Orphai Holdings Therapeutics, Inc., a Delaware corporation ("HoldCo") and Orphai. F2 · derivative.exercise_date: Immediately exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.